Otávio Cesar Baiocchi

Dr. Otávio Cesar Baiocchi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Maria Daniela BergamascoMaria Daniela Bergamasco
Maria Daniela Bergamasco
CPCarlos Alberto P. Pereira
Carlos Alberto P. Pereira
CACelso Arrais-Rodrigues
Celso Arrais-Rodrigues
DFDiogo B. Ferreira
Diogo B. Ferreira
OBOtávio Cesar Baiocchi
Otávio Cesar Baiocchi
Arnaldo L. ColomboArnaldo L. Colombo
Arnaldo L. Colombo
Patients with hematologic malignancies and hematopoietic cell transplant recipients (HCT) are at high risk for invasive fungal disease (IFD). The practice of antifungal prophylaxis with mold-active azoles has been challenged recently because of drug–drug interactions with novel targeted therapies. This is a retrospective, single-center cohort study of consecutive cases of proven or probable IFD, diagnosed between 2009 and 2019, in adult hematologic patients and HCT recipients managed with fluconazole prophylaxis and an antifungal diagnostic-driven approach for mold infection. During the study period, 94 cases of IFD occurred among 664 hematologic patients and 316 HCT recipients. The frequency among patients with allogeneic HCT, autologous HCT, acute leukemia and other hematologic malignancies was 8.9%, 1.6%, 17.3%, and 6.4%, respectively. Aspergillosis was the leading IFD (53.2%), followed by fusariosis (18.1%), candidiasis (10.6%), and cryptococcosis (8.5%). The overall 6-week mortality rate was 37.2%, and varied according to the host and the etiology of IFD, from 28% in aspergillosis to 52.9% in fusariosis. Although IFD occurred frequently in our cohort of patients managed with an antifungal diagnostic driven approach, mortality rates were comparable to other studies. In the face of challenges posed by the use of anti-mold prophylaxis, this strategy remains a reasonable alternative.

8 July 2022 in Immunology Letters
Verified
Journal Article
Closed access
OBOtávio Cesar Baiocchi
Otávio Cesar Baiocchi
AAAndré Abdo
André Abdo
PSPriscilla Brito Silva
Priscilla Brito Silva
AJAmilton Silva Junior
Amilton Silva Junior
LALucas Bassolli de Oliveira Alves
Lucas Bassolli de Oliveira Alves
OBOtavio C.G. Baiocchi
Otavio C.G. Baiocchi

20 December 2023 in eJHaem
Verified
Journal Article
Open access
JVJuliano Cordova Vargas
Juliano Cordova Vargas
KCKarin Zattar Cecyn
Karin Zattar Cecyn
OBOtávio Cesar Baiocchi
Otávio Cesar Baiocchi
JPJuliana Pereira
Juliana Pereira
WBWalter M. Tobias Braga
Walter M. Tobias Braga
OBOtavio C. G. Baiocchi
Otavio C. G. Baiocchi
After initiating combined antiretroviral therapy (cART), individuals with human immunodeficiency virus (HIV) may develop Hodgkin/non-Hodgkin lymphoma due to immune reconstitution inflammatory syndrome (IRIS). This retrospective cohort study evaluated the incidence, clinical features and prognosis of IRIS-associated lymphomas in Brazilian patients. Incidence in 2000-2019 was 9.8% (27/276 patients with HIV and lymphoma; viral load drop >1 log). Time between HIV diagnosis and cART initiation was <1 year in 70.3% of cases. Time between cART initiation and lymphoma diagnosis was <3 months in 11 cases and 3-6 months in 16 cases. Overall and progression-free survival rates were similar between cases of non-IRIS-associated lymphoma and IRIS-associated lymphoma.

18 January 2021 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
OBOtávio Cesar Baiocchi
Otávio Cesar Baiocchi
PMPaulo Goes Manso
Paulo Goes Manso
RARaphael L. C. Araujo
Raphael L. C. Araujo
FBFábio Do Nascimento Brito
Fábio Do Nascimento Brito
JHJamille Elita de Castro Cunha Herculani
Jamille Elita de Castro Cunha Herculani
OBOtávio Cesar Baiocchi
Otávio Cesar Baiocchi
Ocular adnexal lymphoma (OAL) refers to extremely rare, heterogeneous, malignant lymphoproliferative disorder that accounts for 55% of all orbital tumors and 5% of extranodal lymphomas. OAL can com...